Litigation Details for TESSERA TECHNOLOGIES, INC. v. BROADCOM CORPORATION (D.C. 2016)
✉ Email this page to a colleague
TESSERA TECHNOLOGIES, INC. v. BROADCOM CORPORATION (D.C. 2016)
Docket | ⤷ Try a Trial | Date Filed | 2016-07-18 |
Court | District Court, District of Columbia | Date Terminated | |
Cause | Application for Letters Rogatory | Assigned To | |
Jury Demand | None | Referred To | |
Patents | 9,029,081 | ||
Link to Docket | External link to docket |
Biologic Drugs cited in TESSERA TECHNOLOGIES, INC. v. BROADCOM CORPORATION
The biologic drugs covered by the patent cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for TESSERA TECHNOLOGIES, INC. v. BROADCOM CORPORATION (D.C. 2016)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2016-07-18 | 1 | analysis in the nature of trade secrets (Exhibits 9-29, 81-85, 88-90, and 92), a confidential description…75)、保密许可协议 (证据 79、80、87 和 91)、商业秘密性质的保密技术分析(证据 9-29、81-85、88-90 和 92)、 Tessera 在国内行业所进行投资的性质和重要性之保密说明…U.S. Patent Nos. 6,856,007 (“the ’007 patent”); 6,849,946 (“the ’946 patent”); and…infringe Tessera’s patent rights under United States Patent Nos. 6,856,007 (“’007 Patent”), 6,849,946 (“…(“’946 Patent”), and 6,133,136 (“’136 Patent”) (collectively “Asserted Patents”).1 2. The | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |